Relay Therapeutics Reports Promising Data on RLY-2608

The latest announcement is out from Relay Therapeutics ( (RLAY) ).

Relay Therapeutics has announced updated interim clinical data for their investigational drug RLY-2608, presented at the San Antonio Breast Cancer Symposium 2024. The data reveal a median progression-free survival of 11.4 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer treated with RLY-2608 and fulvestrant. The study shows promising efficacy, with a 67% clinical benefit rate and good tolerability. This supports the initiation of a second-line pivotal study in 2025, reflecting potential for significant advancement in treatment options for this patient group.

More about Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company that is transforming the drug discovery process by integrating cutting-edge computational and experimental technologies. The company focuses on developing small molecule therapeutics for targeted oncology and genetic disease indications, utilizing its Dynamo® platform to address challenging protein targets.

YTD Price Performance: -59.76%

Average Trading Volume: 1,809,443

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $741.5M

For detailed information about RLAY stock, go to TipRanks’ Stock Analysis page.